All News
Exciting Data for SLE: Plenaries from #ACR22
ACR Convergence 2022 promises to be another exciting year for research in systemic lupus erythematosus (SLE), with multiple plenary sessions devoted to therapeutic advancements. Here’s a quick rundown of what to expect!
Read Article
Folle et al propose a neural network to differentiate RA+ & RA- vs PsA w/ AUROC 75% & 67% for RA+ vs RA- in 5 distinct hands MRI sequences. Question: what was the performance of the rheumatologist or radiologist?
https://t.co/93aZKPlKsO
Abstr#0242 #ACR22 @Rheumnow https://t.co/uk2c3gbAOT
Aurelie Najm AurelieRheumo ( View Tweet)
Year in Review #ACR22
CAR T cells: deep depletion of CD19 leading to immune reset
5 patients with active SLE
Normalizations of complements, dsDNA
Drug free remission
3 will mild immune reconstitution symptoms, 1 received tocilizumab
@RheumNow
Eric Dein ericdeinmd ( View Tweet)
Nice chart w/JAKs/TYKs by drug and by cytokine pathways
In reality there is a fair bit of crossover and "selectives" aren't nearly as selective as this implies
Helpful to add deucravacitinib to the list! Looking forward to upcoming plenary
#RheumNow #ACR22 #YearInReview https://t.co/MERzpvrFB9
Mike Putman EBRheum ( View Tweet)
Nice summary slide of JAK inhibitors and the history of JAKi in rheumatology,
#ACR22 #ACRambassador https://t.co/Ij2D7YikjT
Vaneet K Sandhu, MD, RhMSUS (she/her) vksandhumd ( View Tweet)
Day 1 #ACR22. Tips to avoid burnout: stretch your legs, a change in scenery for virtual attendees, replenish your sweets and savoury and importantly keep your furry friend happy 🐈⬛ #PetsAtACR @RheumNow #RheumPix https://t.co/opGVSjxLjE
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#acr22 The Rise of JAK in rheumatology
Look for Ab1117 in plenary 2 tomorrow for DEU and SLE
@RheumNow https://t.co/nLpXGyrhfJ
Eric Dein ericdeinmd ( View Tweet)
Dr. C Langford #YearinReview: RDBPCT on benefits/harms prednisolone 5 mg/day for 2 years added to SOC in 65yo+ with active RA. Results: improvement in DAS28 (0.37) but AEs occurred in 24% (infection, low bone density)—NNT 9. Study does not apply to younger pts. #ACR22 @rheumnow https://t.co/p2C6IfSje1
TheDaoIndex KDAO2011 ( View Tweet)
GLORIA trial showing low-dose addon pred in older patients with RA showing modest benefit (including reduction in damage) balanced against increased AEs (mostly infection); NNH 9.5!
@RheumNow #ACR22 #yearinreview #ACRBest
Julian Segan JulianSegan ( View Tweet)
Year in Review #acr22
Oral Surveillance:
With ASCVD number needed to harm 16, only 223 without ASCVD
Focus on risk stratification
@RheumNow https://t.co/tJyha1WKfR
Eric Dein ericdeinmd ( View Tweet)
ORAL surveillance the big talking factor over the last year.
NNH of 16(!) for CV event (over 5 yrs) in those with history of atherosclerotic CV disease.
@RheumNow #ACR22 #yearinreview #ACRBest
Julian Segan JulianSegan ( View Tweet)
Great start to year in review.
Beginning with JAKinibs in the much talked about ORAL Surveillance study.
Good Review of the mechanisms of action for JAKinibs
@RheumNow #ACR22 https://t.co/IF0t4uSefj
Robert B Chao, MD doctorRBC ( View Tweet)
Good grief, no! Why not get a SPECT-CT and arthroscopy on them all as well? Less is more. I will grudgingly get a plain radiograph #ACR22 https://t.co/MVx5FFRsVS
Richard Conway RichardPAConway ( View Tweet)
Abstr #0083 COVID-19 vaccine use & hesitancy among rheum pts
- 34% expressed concern for safety of primary vaccine
- 39% did not get booster due to not being told by physician
- We need to ensure pts up to date w/ vaccine including booster
https://t.co/y1vV7wbbpQ
@RheumNow #ACR22 https://t.co/gcR2yOftjq
Akhil Sood MD AkhilSoodMD ( View Tweet)
#ACR22 Abstr#0355 It can take long time for Class V #lupus nephritis (membranous) to improve. Post-hoc analysis showed in 81 pts (31 pure class V), voclosporin reduced UPCR and faster vs MMF. Stable eGFR @RheumNow #ACRBest https://t.co/gXHxEAU5tq https://t.co/o280DnTmVj
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR22 Abstr#0349 We now have therapies for #lupus. How early should we use them? Real-world data showed 5-year risk of severe infection was reduced in Belimumab vs MTX/AZA/MMF initiators (adjusted to relevant confounders) @RheumNow https://t.co/xXg039zg7m https://t.co/9LEIyoakOY
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Abstr #0078
Ogdie et al found that
- Pts seen by rheumatologists more likely receive bDMARDs or csDMARDs
- Opiates & non-Opiate pain medications were more commonly prescribed to pts seen by PCPs alone
@RheumNow #ACR22
https://t.co/uDcOc0Nn3Y https://t.co/FeAq21fiVs
Akhil Sood MD AkhilSoodMD ( View Tweet)
Year in Review #ACR22
GLORIA
Low steroid usage: lower DAS28, reduced joint damage
BUT 24% increased adverse effects
@RheumNow https://t.co/vYTAhoQEqr
Eric Dein ericdeinmd ( View Tweet)
We want to see how you are taking in #ACR22! Share your favorite pictures from ACR on Twitter and tag #RheumPix and #ACR22 and we'll re-tweet our favorite ones! https://t.co/P41KybUuNw
Dr. John Cush RheumNow ( View Tweet)
Inspiring words from Dr. @cuttingforstone, "For these times, we must heed the call to adventure, find the tools & weapons never thought of before, have courage, have faith, tell our story, find our epiphanies bec this too shall pass..."
#ACR22 @RheumNow #RheumTwitter https://t.co/l3DPnIBxq6
sheila RHEUMarampa ( View Tweet)